Cite
HARVARD Citation
Reck, M. et al. (2023). First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. European journal of cancer. pp. 174-187. [Online].